Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthma: A prospective study

Tomoko Tajiri, Motohiko Suzuki, Hirono Nishiyama, Yoshiyuki Ozawa, Ryota Kurokawa, Keima Ito, Kensuke Fukumitsu, Yuta Mori, Yoshihiro Kanemitsu, Satoshi Fukuda, Takehiro Uemura, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Shinichi Iwasaki, Akio Niimi

研究成果: ジャーナルへの寄稿学術論文査読

1 被引用数 (Scopus)

抄録

Background: Dupilumab exerts clinical effects, including improved sinus opacification, olfactory function, and quality of life, in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNPs). Meanwhile, only a few studies have reported its effects on nasal airway resistance and olfactory function, particularly in the Japanese population. Predictors of response remain unclear. Objective: To assess the comprehensive efficacy and therapeutic response to dupilumab in patients with severe CRSwNP with comorbid asthma. Methods: In 16 adult patients with severe CRSwNP with comorbid asthma, the efficacy of 48-week dupilumab treatment, including olfactory function measured by a T&T olfactometer, nasal airway resistance measured by rhinomanometry, nasal polyp score, Lund-Mackay computed tomography score, and 22-item Sinonasal Outcome Test (SNOT-22), was assessed. Regarding asthma, the annualized rate of exacerbations, 7-item Asthma Control Questionnaire (ACQ-7), and spirometry were assessed. Treatment responsiveness was analyzed. Results: With 48-week dupilumab treatment, olfactory function, nasal airway resistance, nasal polyp score, Lund-Mackay computed tomography score, and SNOT-22 scores improved significantly. Regarding comorbid asthma, the annualized rate of exacerbations decreased, and ACQ-7 scores and lung function improved significantly. According to the European Position Paper on Rhinosinusitis and Nasal Polyps 2020/European Forum for Research and Education in Allergy and Airway Diseases criteria, 15 patients (94%) were moderate-to-excellent responders at 48 weeks of treatment. Patients with higher SNOT-22 scores, ACQ-7 scores, the rate of asthma exacerbations in the previous year, and blood eosinophil counts benefited more from the treatment. Conclusion: Dupilumab improved upper and lower airway outcomes especially in patients with severe CRSwNP with comorbid, poorly controlled asthma. Trial Registration: UMIN Clinical Trials Registry: UMIN000038669.

本文言語英語
ページ(範囲)550-558.e2
ジャーナルAnnals of Allergy, Asthma and Immunology
133
5
DOI
出版ステータス出版済み - 11-2024

All Science Journal Classification (ASJC) codes

  • 免疫アレルギー学
  • 免疫学
  • 呼吸器内科

フィンガープリント

「Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthma: A prospective study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル